Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
Overview
Stock Information
Nasdaq:
COCPPrice

Change

Mkt Cap

Volume

52 week Low/High

Day Low/High
